Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) shares were up 5.5% during mid-day trading on Friday . The company traded as high as $47.00 and last traded at $47.00. 17,722 shares were traded during mid-day trading, a decline of 93% from the average daily volume of 271,911 shares. The stock had previously closed at $44.53.
Analyst Ratings Changes
A number of equities analysts recently weighed in on COAG shares. Wedbush reissued an “outperform” rating and set a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a report on Monday. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Evercore initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price target on the stock. HC Wainwright upped their price objective on shares of Hemab Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a research note on Monday. Finally, The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.00.
View Our Latest Stock Report on Hemab Therapeutics
Hemab Therapeutics Stock Up 7.9%
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last announced its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.
Insider Activity at Hemab Therapeutics
In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the acquisition, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. This represents a 77.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have acquired 2,970,541 shares of company stock valued at $55,459,603 over the last quarter.
About Hemab Therapeutics
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.
Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.
Read More
- Five stocks we like better than Hemab Therapeutics
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
- Sandisk: What the Chart Is Trying to Tell Us
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
